Drug Approval | August 28, 2021
Japan approves AstraZeneca’s Forxiga for chronic kidney disease
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
The hospital works in close collaboration with the Network for Organ Sharing and the National Organ & Tissue Transplant Organisation (NOTTO) and it is amongst the very few hospitals doing ABO-incompatible transplant
The new unit is expected to serve thousands of patients annually, helping address a critical gap in dialysis access
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
Backed by funding from an NIHR Doctoral Award, the guidance is focused on spotting abdominal tumours
Integrated multidisciplinary model positions Hyderabad as a growing referral hub for advanced pediatric care
The new single-pill therapy combines cilnidipine, telmisartan and metoprolol, bringing together three established antihypertensive agents with complementary mechanisms
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
Analysis of over 93 lakh preventive health checkups reveals disease risks emerging as early as the 20s
Subscribe To Our Newsletter & Stay Updated
